Microbiome analysis in Lithuania: overview of the global and Lithuanian ecosystem, strengths, weaknesses, and recommendations

Authors: Ieva Juzumaitė and Greta Šimeliūnaitė

Project owner: Dr. Karolina Trakšelytė-Rupšienė and Paulius Kamaitis

2025 02 28

SWOT Analysis of the Lithuanian Microbiome Sector

To evaluate the current state of the microbiome sector in Lithuania and identify opportunities for growth, we have conducted a SWOT analysis. This analysis provides an overview of the sector's strengths, weaknesses, opportunities, and threats, offering insights into its competitive position, challenges, and potential pathways for future development.

Below is the SWOT analysis of Lithuania's microbiome sector:

Strengths	Weaknesses
Technological Advancements: • Access to cutting-edge technologies like CRISPR, which enable advanced microbiome research.	**Knowledge and Talent Development:** • Limited public knowledge about the microbiome field and its significance. • Lack of exchange programs for postgraduate students to go abroad and expand networks. • Current study programs are not well-adapted for the development of specialized fields such as bioinformatics, limiting the training of experts essential for life science sector.
Universities and Collaborations: • Leading universities with high-competency specialists drive research in Lithuania • Many international collaborations with leading universities and pharmaceutical and biotechnology companies. • New centers, such as the Medical Science Center, support interdisciplinary collaboration and research.	**Funding and Investment:** • Calls and grants do not specifically mention microbiome topics. • Government funding does not meet the sector's needs to provide sufficient support for large-scale or long-term projects crucial to the expansion and development of the microbiome sector, impacting product commercialization.

Support and Funding: • Availability of national and EU funding that indirectly supports microbiome research projects. • Funding programs by governmental institutions help develop favorable conditions for start-ups to create and grow.	**Infrastructure and Resources:** • High cost of clinical trials and DNA sequencing in local institutions, making outsourcing to other countries more feasible. • There are few incentives to modernize or renew research infrastructure, and untapped opportunities to utilize existing facilities.
	Regulations and Bureaucracy: • Regulatory pathways and framework should be improved for food supplements and microbiome-based therapies and drugs in both the EU and Lithuania to make it easier for products to go to market. • Public procurement policies are not favorable for supporting clinical trials and scientific research. • Local documentation requirements impose additional constraints on business development.
	Industry-Academia Collaboration: • Difficulty initiating clinical trials due to the limited presence of pharmaceutical companies in Lithuania. • Weak collaboration between industry and academia due to high costs, different priorities, and time constraints. • Few companies invest in research-backed, scientifically tested products.

Opportunities	Threats
Specialization: • Lithuania has an opportunity to carve out a unique identity in the emerging microbiome field due to its relative newness in this area. • By specializing in specific technologies such as CRISPR, tissue engineering, and microfluidics, Lithuania can attract foreign investors and stand out globally.	**Talent Drain:** • Skilled professionals in all fields are migrating abroad for better opportunities leading to brain drain.
Market Position and Ecosystem: • The rising global microbiome sector aligns well with Lithuania's Life Sciences Roadmap goal to reach 5% by 2030. • With limited competition in the microbiome field within Lithuania, there is a unique opportunity for the country to establish itself as a regional leader in microbiome research and applications. • Favorable conditions for new biotech companies to enter the microbiome market, fostering innovation, creating jobs, and attracting international investment.	**Regulatory Challenges:** • Lack of clear and supportive regulations hinders the start and growth of product development in the microbiome sector. • Slow approval processes by the European Medicines Agency (EMA) for drugs and the European Food Safety Authority (EFSA) for functional foods delay market introductions.
Partnerships: • Strong international partnerships with leading universities and pharmaceutical companies provide an opportunity to enhance knowledge exchange, drive innovation, and elevate Lithuania’s global presence in microbiome research.	**Global Competition:** • As the microbiome sector grows, Lithuania may face increasing competition from other countries with more established programs and resources.
	Public Awareness: • Limited awareness and support for the microbiome sector may hinder investment and collaboration.